Preparation and efficacy of newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zhao, Kai ^a,b   Li, Wei ^a,b   Huang, Tingting ^a,b   Luo, Xiaomei ^a   Chen, Gang ^a   Zhang, Yang ^a,b   Guo, Chen ^a   Dai, Chunxiao ^a   Jin, Zheng ^a   Zhao, Yan ^b   Cui, Hongyu ^b   Wang, Yunfeng ^b  

^a HEILONGJIANG UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEWCASTLE DISEASE VACCINE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CELLULAR IMMUNITY; CHICKEN; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVAPORATION; FUSION GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MUCOSAL IMMUNITY; NANOENCAPSULATION; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARTICLE SIZE; PLASMID; SUSTAINED DRUG RELEASE; VIRUS GENE; ZETA POTENTIAL;

ANIMALS; CHICKENS; DRUG CARRIERS; LACTIC ACID; NANOPARTICLES; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; POLYGLYCOLIC ACID; POULTRY DISEASES; VACCINES, DNA;

EID: 84891308894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082648     Document Type: Article

References (43)

1. Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16: 1-15. (Pubitemid 30066477)
2. Mast J, Nanbru C, Decaesstecker M, Lambrecht B, Couvreur B, et al. (2006) Vaccination of chicken embryos with escape mutants of La Sota Newcastle disease virus induces a protective immune response. Vaccine 24: 1756-1765. (Pubitemid 43238256)
3. Tseng LP, Chiou CJ, Deng MC, Lin MH, Pan RN, et al. (2009) Evaluation of encapsulated Newcastle disease virus liposomes using various phospholipids administered to improve chicken humoral immunity. J Biomed Mater Res B 91: 621-625.
4. Miller PJ, King DJ, Afonso CL, Suarez DL (2007) Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge. Vaccine 25: 7238-7246. (Pubitemid 47464666)
5. Meulemans G, Gonze M, Carlier MC, Petit P, Burny A, et al. (1986) Protective effects of HN and F glyprotein-specific monoclonal antibodies on experimental Newcastle disease. Avian Pathol 15: 761-768.
6. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175: 633-639. (Pubitemid 41094942)
7. Xu K, Ling ZY, Sun L, Xu Y, Bian C, et al. (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 24: 45-56.
8. Hallengard D, Haller BK, Petersson S, Boberg A, Maltais AK, et al. (2011) Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29: 839-848.
9. Abbas AO, Donovan MD, Salem AK (2008) Formulating Poly (Lactide-co- Glycolide) particles for plasmid DNA delivery. J Pharm Sci 97: 2448-2461.
10. Intra J, Salem AK (2010) Fabrication Characterization and in vitro evaluation of poly (D, L -Lactide- co-Glycolide) microparticles loaded with polyamidoamine- plasmid DNA dendriplexes for applications in nonviral gene delivery. J Pharm Sci 99: 368-384.
11. Wu H, Dennis VA, Pillai SR, Singh SR (2009) RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res 145: 39-47.
12. Wang T, Upponi JR, Torchilin VP (2012) Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies. Int J Pharm 427: 3-20.
13. Kim YC, Song JM, Lipatov AS, Choi SO, Lee JW, et al. (2012) Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm 81: 239-247.
14. Conese M, Ascenzioni F, Boyd AC, Coutelle C, Fino ID, et al. (2011) Gene and cell therapy for cystic fibrosis. Bench to Bedside J Cyst Fibros 10: S114-S128.
15. Fowler V, Robinson L, Bankowski B, Cox S, Parida S, et al. (2012) A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease. Res Antivir 94: 25-34.
16. Singh M, Hagan DT (2002) Recent advances in vaccine adjvants. Pharm Res 19: 715-720.
17. Shi Z, Curiel DT, Tang DC (1999) DNA-based non-invasive vaccination onto the skin. Vaccine 17: 2136-2141. (Pubitemid 29197280)
18. Csaba N, Fuentes MG, Alonso MJ (2006) The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Del 3: 463-478.
19. Moghimi SM, Kissel T (2006) Particulate nanomedicines. Adv Drug Deliver Rev 58: 1451-1455. (Pubitemid 44820501)
20. Liang MT, Davies NM, Blanchfield JT, Toth I (2006) Particulate systems as adjuvant and carriers for peptide and protein antigens. Curr Drug Deliv 3: 379-388. (Pubitemid 44534050)
21. Malhotra M, Lane C, Duchesneau CT, Saha S, Prakash S (2011) A novel method for synthesizing PEGylated chitosan nanoparticles, strategy, preparation, and in vitro analysis. Int J Nanomed 6: 485-494.
22. Zhao K, Shi XM, Zhao Y, Wei HX, Sun QS, et al. (2011) Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29: 8549-8556.
23. Shakweh M, Besnard M, Nicolas V, Fattal E (2005) Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in mice. Eur J Pharm Biopharm 61: 1-13. (Pubitemid 41096683)
24. Ribeiro S, Hussain H, Florence AT (2005) Release of DNA from dendriplexes encapsulated in PLGA nanoparticles. Int J Pharm 298: 354-360. (Pubitemid 40910742)
25. Mollenkopfa HJ, Dietrichb G, Fensterlea J, Grodea L, Diehl KD, et al. (2004) Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22: 2690-2695.
26. Costantino L, Gandolfi F, Bossy-Nobs L, Tosi G, Gurny R, et al. (2006) Nanoparticulate drug carriers based on hybrid poly (D, L-lactide-co-glycolide)- dendron structures. Biomaterials 27: 4635-4645. (Pubitemid 43783224)
27. Elkharraz K, Faisant N, Guse C, Siepmann F, Yegin BA, et al. (2006) Paclitaxelloaded microparticles and implants for the treatment of brain cancer, preparation and physicochemical characterization. Int J Pharm 314: 127-136.
28. Fievez V, Plapied L, Rieux AD, Pourcelle V, Freichels H, et al. (2009) Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination Eur J Pharm Biopharm 73: 16-24.
29. Mishra N, Tiwari S, Vaidya B, Agrawal GP, Vyas SP (2011) Letin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target 19: 67-78.
30. Slü tter B, Plapied L, Fievez V, Sande MA, Rieux AD, et al. (2009) Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 138: 113-121.
31. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, et al. (2009) Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune responses and protection against infection. Vaccine 27: 3643-3649.
32. Csaba N, Sanchez A, Alonso MJ (2006) PLGA, poloxamer and PLGA, Poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release 113: 164-172. (Pubitemid 43928142)
33. Marazuela EG, Prado N, Moro E, Garc?́a HF, Villalba M, et al. (2008) Intranasal vaccination with poly (lactide-co-glycolide) microparticles containing a peptide T of Ole 1 prevents mice against sensitization. Clin Exp Allergy 38: 520-528. (Pubitemid 351208087)
34. Dillen K, Weyenberg W, Vandervoort J, Ludwig A (2004) The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles. Eur J Pharm Biopharm 58: 539-549. (Pubitemid 39297100)
35. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endolysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 16: 1217-1226. (Pubitemid 34815409)
36. Stern M, Ulrich K, Geddes DM, Alton E (2003) Poly, L-lactide-co- glycolide/ DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther 10: 1282-1288. (Pubitemid 36987118)
37. Ho J, Wang H, Forde GM (2008) Process considerations related to the microcapsulation of plasmid DNA via ultrasonic atomization. Biotechnol Bioeng 101: 172-181.
38. Rajapaksa TE, Hamer MS, Fernandez X, Eckelhoefer HA, Lo DD (2010) Caludin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 142: 196-205.
39. Zhao K, Li GX, Jin YY, Wei HX, Sun QS, et al. (2010) Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres. J Microencapsul 27: 178-186.
40. Ugwoke MI, Agu RU, Verbeke N, Kinget R (2005) Nasal mucoadhesive drug delivery, Background, applications, trends and future perspectives. Adv Drug Deliver Rev 57: 1640-1665. (Pubitemid 41443473)
41. Basarkar A, Devineni D, Palaniappan R, Singh J (2007) Preparation, characterization, cytotoxicity and transfection efficiency of poly (D, L-lactideco- glycolide) and poly (D, L-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm 343: 247-254. (Pubitemid 47334869)
42. Panyam J, Labhasetwar V (2012) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliver Rev 64: 61-71.
43. Neutra MR, Frey A, Kraehenbuhl JP (1996) Epithelial M cell, gate ways for mucosal infection and immunicazation. Cell 86: 345-348. (Pubitemid 26272074)